Cleveland BioLabs, Inc. (CBLI)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.86-0.04 (-2.11%)
At close: 4:00 PM EDT
People also watch:
CYCCCLSNAVEOABIOCYTX
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open1.96
Prev Close1.90
Bid1.32 x 200
Ask2.65 x 1200
Day's Range1.85 - 1.98
52wk Range1.79 - 5.29
1y Target EstN/A
Market Cap19.94M
P/E Ratio (ttm)-2.81
Beta-1.05
Volume38,323
Avg Vol (3m)20,030
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Capital Cube15 hours ago

    ETF’s with exposure to Cleveland BioLabs, Inc. : August 30, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Cleveland BioLabs, Inc. Here are 5 ETF’s with the largest exposure to CBLI-US. Comparing the performance and risk of Cleveland BioLabs, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q2, 2016 By the Numbers : August 18, 2016
    Capital Cube13 days ago

    Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q2, 2016 By the Numbers : August 18, 2016

    Categories: Yahoo Finance Get free summary analysis Cleveland BioLabs, Inc. reports financial results for the quarter ended June 30, 2016. We analyze the earnings along side the following peers of Cleveland BioLabs, Inc. – Onconova Therapeutics Inc., OPKO Health, Inc., Novartis AG Sponsored ADR, Bristol-Myers Squibb Company, Cascadian Therapeutics Inc., Amgen Inc., Eli Lilly and Company and GlaxoSmithKline ... Read more (Read more...)

  • Marketwired16 days ago

    Cleveland BioLabs Reports Second Quarter 2016 Financial Results and Development Progress

    Cleveland BioLabs, Inc. today reported financial results and development progress for the second quarter ended June 30, 2016.